^
Association details:
| Biomarker: | ERCC1 underexpression |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | cisplatin (DNA synthesis inhibitor) + pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial
Published date:
10/06/2021
Excerpt:
We assessed the efficacy and tolerability of pemetrexed and cisplatin combination therapy in patients with refractory bone and soft tissue sarcoma (STS)....Among 26 patients (70.3%) available for immunohistochemical assessments, patients in the low-excision repair cross-complementation group 1 (ERCC1) and low-thymidylate synthase expression groups showed a tendency for longer overall survival.
DOI:
10.1016/j.esmoop.2021.100249
Trial ID:
